Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.56 |
| ▸ | MAOB | P27338 | 5/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | CMA1 | P23946 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891129 | 0.89 | IDO1 (0.54) | MAOAMAOBIDO1NPC1MAPK13 | |
| SCHEMBL30320568 | 0.89 | IDO1 (0.58) | MAOAMAOBIDO1NPC1MAPK13 | |
| SCHEMBL3627854 | 0.89 | IDO1 (0.58) | MAOAMAOBIDO1NPC1MAPK13 | |
| SCHEMBL4596554 | 0.86 | KIF11 (0.68) | MAOAMAOBIDO1NPC1MAPK13 | |
| SCHEMBL7214466 | 0.86 | BRD4 (0.52) | MAOAMAOBIDO1CMA1AHR | |
| SCHEMBL2220942 | 0.85 | CMA1 (0.70) | MAOAMAOBIDO1NPC1MAPK13 | |
| SCHEMBL29754270 | 0.85 | CMA1 (0.70) | MAOAMAOBIDO1NPC1MAPK13 | |
| SCHEMBL27371363 | 0.83 | CMA1 (0.46) | MAOAMAOBIDO1NPC1MAPK13 | |
| SCHEMBL6431 | 0.82 | AHR (0.72) | IDO1CMA1AHRBRD4PDE3B | |
| SCHEMBL1185219 | 0.78 | KMT2A (0.54) | MAOAMAOBIDO1CMA1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4648853-A1 | TARGETED DEGRADATION OF VAV1 | Monte Rosa Therapeutics AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-06-26 | — | — | US | disclosed |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12257247-B2 | Targeted degradation of VAV1 | MONTE ROSA THERAPEUTICS AG (CH) | 2025-03-25 | — | — | US | disclosed |
| US-20250084055-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | C4 THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | US | disclosed |
| CN-119504726-A | BRD4 inhibitor and preparation method and application thereof | 四川大学华西医院 | 2025-02-25 | — | — | CN | disclosed |
| WO-2025021062-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119384413-A | Anilino-pyrazole derivatives, compositions and methods thereof | 昂胜医药有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119371412-A | CYP11B2 inhibitor compound, pharmaceutical composition and application thereof | 长春金赛药业有限责任公司 | 2025-01-28 | — | — | CN | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-5306719-A | Cardiotonic agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0255134-B1 | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | disclosed |
| US-5071856-A | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-10 | — | — | US | disclosed |
| US-4921862-A | Carbostyril derivatives as combined thromboxane synthetase and cyclic-amp phosphodiesterase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1990-05-01 | — | — | US | disclosed |
| US-4886809-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| US-4792561-A | ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1988-12-20 | — | — | US | disclosed |
| EP-0255134-A2 | Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-03 | — | — | EP | disclosed |
| US-4710507-A | Quinolone inotropic agents | PFIZER INC. (US) | 1987-12-01 | — | — | US | disclosed |
| EP-0148623-A2 | Quinolone inotropic agents | Pfizer Limited (GB) | 1985-07-17 | — | — | EP | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12257247-B2 | Targeted degradation of VAV1 | VAV1, KRAS, CBL | MAOA 4469/4885MAOB 4558/4885IDO1 2582/4885 |
| US-20250084055-A1 | DIHYDROQUINOLINONES FOR MEDICAL TREATMENT | CRBN, RBX1, ADRM1 | MAOA 3897/4885MAOB 3570/4885IDO1 4053/4885 |
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | MAOA 552/4885MAOB 135/4885IDO1 3058/4885 |
| US-20250205219-A1 | TARGETED DEGRADATION OF VAV1 | VAV1, KRAS, CBL | MAOA 4469/4885MAOB 4558/4885IDO1 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.